dc.contributor.author | Richardson, Paul Gerard Guy | |
dc.contributor.author | Laubach, Jacob | |
dc.contributor.author | Schlossman, Robert Lawrence | |
dc.contributor.author | Ghobrial, Irene | |
dc.contributor.author | Mitsiades, Constantine S | |
dc.contributor.author | Rosenblatt, Jacalyn Mara | |
dc.contributor.author | Mahindra, Anuj | |
dc.contributor.author | Raje, Noopur | |
dc.contributor.author | Munshi, Nikhil C | |
dc.contributor.author | Anderson, Kenneth Carl | |
dc.date.accessioned | 2013-02-14T19:10:32Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Richardson, Paul G., Jacob P. Laubach, Robert L. Schlossman, Irene M. Ghobrial, Constantine S. Mitsiades, Jacalyn Rosenblatt, Anuj Mahindra, et al. 2011. The Medical Research Council myeloma IX trial: The impact on treatment paradigms. European Journal of Haematology 88(1): 1-7. | en_US |
dc.identifier.issn | 0902-4441 | en_US |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:10297258 | |
dc.description.abstract | Osteolytic bone disease is a hallmark of symptomatic multiple myeloma. Bisphosphonates have been the mainstay of treatment to preserve skeletal integrity and prevent skeletal-related events in patients with myeloma-related bone disease. Recently, the MRC Myeloma IX trial demonstrated for the first time improved survival and delayed disease progression with the use of an intravenous amino-bisphosphonate, zoledronic acid, vs. an oral agent, clodronate, with intensive and non-intensive anti-myeloma treatment regimens in patients with newly diagnosed multiple myeloma. These results validate a large body of preclinical, translational and other clinical data suggesting anti-myeloma effects of amino-bisphosphonates. In addition, this trial also provided the first head-to-head evidence for superiority of one bisphosphonate over another (zoledronic acid vs. clodronate) for reducing skeletal morbidity in patients with multiple myeloma, as well as a prospective comparison of toxicities. Despite the use of non-bortezomib containing anti-myeloma treatment regimens in the MRC Myeloma IX trial, these results are encouraging and provide an impetus to continue to evaluate current treatment guidelines for myeloma-associated bone disease. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.relation.isversionof | doi:10.1111/j.1600-0609.2011.01721.x | en_US |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267050/pdf/ | en_US |
dash.license | LAA | |
dc.title | The Medical Research Council Myeloma IX Trial: The Impact on Treatment Paradigms | en_US |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en_US |
dc.relation.journal | European Journal of Haematology | en_US |
dash.depositing.author | Richardson, Paul Gerard Guy | |
dc.date.available | 2013-02-14T19:10:32Z | |
dc.identifier.doi | 10.1111/j.1600-0609.2011.01721.x | * |
dash.authorsordered | false | |
dash.contributor.affiliated | Schlossman, Robert Lawrence | |
dash.contributor.affiliated | Mahindra, Anuj | |
dash.contributor.affiliated | Rosenblatt, Jacalyn | |
dash.contributor.affiliated | Mitsiades, Constantine | |
dash.contributor.affiliated | Ghobrial, Irene | |
dash.contributor.affiliated | Laubach, Jacob | |
dash.contributor.affiliated | Richardson, Paul | |
dash.contributor.affiliated | Raje, Noopur | |
dash.contributor.affiliated | Munshi, Nikhil | |
dash.contributor.affiliated | Anderson, Kenneth | |